China Resources Pharmaceutical Group (HKSE:03320) Debt-to-Equity : 1.58 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Debt-to-Equity?

China Resources Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$58,635 Mil. China Resources Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$23,363 Mil. China Resources Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$52,068 Mil. China Resources Pharmaceutical Group's debt to equity for the quarter that ended in Jun. 2024 was 1.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Resources Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

HKSE:03320' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.68 Med: 1.3 Max: 1.82
Current: 1.58

During the past 11 years, the highest Debt-to-Equity Ratio of China Resources Pharmaceutical Group was 1.82. The lowest was 0.68. And the median was 1.30.

HKSE:03320's Debt-to-Equity is ranked worse than
93.1% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs HKSE:03320: 1.58

China Resources Pharmaceutical Group Debt-to-Equity Historical Data

The historical data trend for China Resources Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Debt-to-Equity Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.01

0.95

1.12

1.07

1.35

China Resources Pharmaceutical Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															1.40	1.07	1.52	1.35	1.58

Competitive Comparison of China Resources Pharmaceutical Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Pharmaceutical Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's Debt-to-Equity falls into.

China Resources Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Resources Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(50558.386	+	17431.961)	/	50269.646
	=	1.35

China Resources Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(58635.326	+	23362.806)	/	52068.105
	=	1.57

China Resources Pharmaceutical Group (HKSE:03320) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

China Resources Pharmaceutical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Debt-to-Equity

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma's manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group Headlines

No Headlines